Acute Lymphoblastic Leukemia (ALL) is the most common hematological malignancy diagnosed in childhood. So as more and more new pediatric ALL treatments and regimens have been modified for better treatment options and outcomes. By reviewing the history, current status, and future prospects for the therapy of pediatric ALL, concentrating on interventions and biology while excluding children ALL and relapsed/refractory ALL, which have been reported in other cases, will help us have a better understanding of this major childhood cancer management.